Answers are grounded in this paper and cite their sources.
Immunotherapies have revolutionized cancer care, however there are increasing cases of complications including overlapping syndromes which are difficult to manage. Triple M (myocarditis-myositis-myasthenia gravis) syndrome is a rare and severe complication of immune checkpoint inhibitor (ICI) therapy with no clear consensus of management. We present a case of a male in his seventies, with malignant pleural mesothelioma (MPM) undergoing ICI therapy who subsequently developed Triple M Syndrome. Despite aggressive therapeutic interventions with high steroids and therapeutic plasma exchange (TPE), the patient's condition deteriorated rapidly leading to death. This case highlights the challenges in diagnosis and management of triple M syndrome, as not all three components of the triad are always immediately apparent, therefore early clinical recognition and, multidisciplinary involvement in management is crucial to neurologists.
No takes yet. Share an insight, caveat, or question.
Varghese et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: